Connect with us

Agreements

New Agreement – Recyclable Cap Format for Water Coolers

Betty Tűndik

Published

on

Cealsius Heat Brand - Photo Source: celsiusholdingsinc.com
Reading Time: 4 minutes

 

Celsius Holdings, Inc. (Nasdaq: CELH), maker of the leading global fitness drink, CELSIUS® has announced an agreement with Lavit, LLC (“Lavit”), an eco-friendly, beverage technology company, to offer its energy drinks for Lavit’s cold, still and sparkling water coolers in select office locations.

Under the terms of the agreement, Celsius will initially offer its orange flavor in Lavit’s EcoCaps™, a recyclable variation on Keurig’s single-use disposable K-Cup model that are designed to work specifically with Lavit’s water coolers. Lavit’s on-demand beverage coolers eliminate the need to stock office refrigerators with bottles and cans of beverages and offer healthier alternatives to sugary sodas. The EcoCaps will utilize the same formula as Celsius’ popular powder format. Each EcoCap is made from 100% aluminum, and thus 100% recyclable.

Celsius’ energy drink includes no artificial preservatives or flavors, no aspartame or high fructose corn syrup and is clinically-proven to accelerate metabolism, burn calories and body fat and provide healthy energy, making it an excellent alternative to coffee or energy drinks.

“Our relationship with Lavit further adds to our distribution network and represents a powerful way for us to increase brand awareness and exposure of our beverages, reaching a population of consumers in a new environment,” commented John Fieldly, President and Chief Executive Officer of Celsius Holdings, Inc. “With Lavit, we are able to offer our energy drinks conveniently to offices nationwide and meet the growing demand for alternative beverages in the workplace.”

“Lavit is thrilled to add CELSIUS® healthy energy drinks to our growing cold still and sparkling platform,” commented Sam Murray, CEO of Lavit. “Their refreshing and functional line fits perfectly with Lavit’s goal of providing better for you beverages and enhanced waters for workplaces that are striving to provide healthy hydration and sustainable solutions.”

Lavít (pronounced “LA-veet”), founded in 2011 and headquartered in New York City, is an eco-friendly, beverage technology company seeking to disrupt the multi-billion-dollar bottling industry. The company’s Water Cooler™ helps personalize the way people stay hydrated by allowing them to craft the cold beverage of their choice in seconds with just a push of a button. Beverage options include still or sparkling water or they can choose from a growing roster of popular brands and flavors – all with zero preservatives and just 10 calories or less per 12-ounce serving. Users craft their beverages by inserting fully recyclable aluminum flavor capsules (EcoCaps™) into a Lavit cooler and then adjusting flavor intensity and carbonation level. For every EcoCap sold, Lavit donates to onedrop.org, providing clean drinking water for those in need around the world. Learn more at www.drinklavit.com.

 

Celsius Holdings, Inc. (Nasdaq: CELH) was founded in April 2004, and it is a global company that has a branded portfolio consisting of two beverage lines; each offering proprietary, functional, healthy-energy formulas that are clinically-proven to offer significant health benefits to its users. The CELSIUS® Original Line comes in nine delicious sparkling and non-carbonated flavors in sleek 12oz cans and is also available in single-serve powder packets in four on-the-go, enjoyable flavors. The CELSIUS® Stevia Line is an extension of the original line offering naturally-caffeinated and naturally-sweetened and is available in five refreshing sparkling and non-sparkling flavors.

New to the portfolio is CELSIUS HEAT™, which offers an additional 100mg of caffeine than the Original and Stevia extension, for a total of 300mg per can. It also contains 2,000mg of L-citrulline, a vasodilator. CELSIUS HEAT™ is sold in 16oz cans, is available in five carbonated flavors and was developed for those seeking a bolder version of the Original and Stevia line extension – which are sold in 12oz cans and appeal to the masses as an active lifestyle brand. As with all CELSIUS® products, CELSIUS HEAT™ is a thermogenic and is an ideal 16oz energy drink given it is proven-to-function and is healthier than competitive 16oz traditional energy drinks with high sugar content. CELSIUS HEAT™ targets millennial fitness enthusiasts, avid gym goers, professional trainers, competitive athletes, the military and first responders.

CELSIUS® has zero sugar, no preservatives, no aspartame, no high fructose corn syrup, and is non-GMO, with no artificial flavors or colors. The CELSIUS® line of products is Certified Kosher and Vegan. CELSIUS® is also soy and gluten-free and contains very little sodium. CELSIUS® is sold nationally through dominant fitness channel distributors and retailers, The Vitamin Shoppe, GNC, Amazon.com, Walmart.com, Target, 7- Eleven, Sprouts, The Fresh Market and other key regional retailers such as HEB, Publix, Winn-Dixie, Harris Teeter, Shaw’s, Food Lion, CVS and many more.

*CELSIUS®’ functional claims are backed by six published university studies. The first study was conducted in 2005 and additional studies from the University of Oklahoma were conducted over the next five years. The studies were published in peer-reviewed journals and validate the unique benefits that CELSIUS® provides.

 

Forward-Looking Statements 

This press release may contain statements that are not historical facts and are considered forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements contain projections of Celsius Holdings, Inc.’s future results of operations and/or financial position, or state other forward-looking information. In some cases, you can identify these statements by forward-looking words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “should,” “will,” “would,” or similar words. You should not rely on forward-looking statements since Celsius Holdings’ actual results may differ materially from those indicated by forward-looking statements as a result of a number of important factors. These factors include, but are not limited to: general economic and business conditions; our business strategy for expanding our presence in our industry; anticipated trends in our financial condition and results of operation; the impact of competition and technology change; existing and future regulations affecting our business; and other risks and uncertainties discussed in the reports Celsius Holdings has filed previously with the Securities and Exchange Commission. Celsius Holdings does not intend to and undertakes no duty to update the information contained in this press release.

 

SOURCE: Celsius Holdings, Inc.

Hi everyone! Nice to e-meet you! Here are a few things you should know about me.


I am a conscientious, open minded, adaptable to new experiences and ambitious Business Development Manager with a Bachelor's Degree in Economics - Banking, Finance and Accountancy. Through my studies I've also obtained many naturopathic and nutrition degrees as well. Part-time jobs have added marketing, network marketing, event management and store management skills to my experience through my career.


Through my career I have also been a Hotel Manager and owned a Bar/Restaurant & Internet Cafe. My online marketing and social media interactivity experience was gained when me and my husband started a business with an online/organic webshop & healthy lifestyle consultancy.


I've improved my English at Cambridge Academy of English - 2003, in Cambridge. I live a conscious lifestyle, and try to protect the ecosystem. Animal lover and capable of helping others without judgement or negative reactions, this is thanked to my knowledge in holistic therapies and the naturopathy courses I've followed.


I cannot leave far my spiritual growth and the continuous development in alternative and holistic therapies, so I'm learning at Kyron School of New Consciousness, receiving a Bio Energo-therapist diploma.


Thanks to all my experiences I've decided to venture into publishing and writting, while also continuing to learn many new things daily. I hope you enjoy reading my hand picked PICANTE News and check back for my weekly articles. You can find my articles and news digests in the following categories:


FOOD & BEVERAGES, ANIMALS/PETS, ANIMAL WELFARE, CANNABIS, ENTERTAINMENT, HEALTH CARE/HOSPITALS, CONSUMER & COSMETICS, ART, HEALTH AND LIFESTYLE, ALTERNATIVE ENERGIES, BEVERAGES, ALTERNATIVE MEDICINE, COSMETICS AND PERSONAL CARE, AGRICULTURE, and many more.



You can get in touch to discuss interviews or possible article submissions by contacting us.


Let's also connect via social media! You can find me on LinkedIn and Twitter.

Advertisement
Comments

Agreements

Pie Five Signs First Franchise Agreement In Oregon

Betty Tűndik

Published

on

Pie Five is bringing fresh ingredients and custom pizzas to Corvallis, Oregon
Reading Time: 1 minute

 

Fast-casual pizza brand bringing fresh ingredients and custom pizzas to Corvallis

Pie Five Pizza announced that the fast-casual pizza chain has signed a two store deal in Corvallis, Oregon. This will be the first Pie Five location to open in the Beaver State.

Ravi and Sharna Prasad signed an agreement to bring Pie Five to Corvallis later this year. The Prasads reside in Corvallis which is also home to Oregon State University and Hewlett-Packard.

“Sharna and I didn’t come to this decision lightly,” Ravi Prasad said. “We researched nine other similar concepts before choosing Pie Five. We were impressed with Pie Five’s quality ingredients and their superior oven technology – they have the fastest oven in the industry. But what really won us over was the Pie Five team. The entire team has been friendly and supportive. We’re confident in the brand and know we’re in good hands for our first franchise.”

Pie Five’s fast-casual concept provides guests with a fully customizable experience from start to finish. With more than 30 fresh toppings, six savory sauces and five crust choices, there’s a delicious pairing to match every guest’s preference. In addition to offering low-carb Cauliflower Crust, Pie Five accommodates dietary restrictions with its gluten-free crust and vegan cheese options.

“I couldn’t be more excited to welcome the Prasads to the Pie Five family,” said RAVE President Bob Bafundo. “We’re proud to partner with Ravi and Sharna to bring Pie Five’s fast and fresh handcrafted pizzas to the community of Corvallis.”

For more information on Pie Five’s locations, please visit the Pie Five location finder.

Connect with Pie Five on FacebookInstagram and Twitter.

 

SOURCE: Pie Five Pizza

 

Continue Reading

Agreements

Partnership to focus on Alzheimer’s disease, breast cancer, diabetes, obesity

Betty Tűndik

Published

on

Reading Time: 8 minutes

 

Centene Corporation (NYSE: CNC) and Washington University School of Medicine in St. Louis announced today a partnership to transform and accelerate research into treatments for Alzheimer’s disease, breast cancer, diabetes and obesity. All are common, debilitating and often deadly diseases that affect millions of people worldwide, at all levels of income.

As part of the partnership, Centene will fund up to $100 million over 10 years in research at Washington University. The funding will galvanize the School of Medicine’s Personalized Medicine Initiative, which aims to develop customized disease treatment and prevention for patients. Innovations that arise from the initiative will be commercialized through the ARCH Personalized Medicine Initiative, a joint venture between the School of Medicine and Centene. Reflecting the philosophy of both institutions, ARCH is designed to accelerate the development and implementation of affordable and accessible health solutions to the public using the intellectual property developed from this research.

“We share the goal of helping to improve the health of our communities through research, education and customized treatment for people suffering from chronic illnesses,” said Michael F. Neidorff, chairman and CEO for Centene. “We believe personalized medicine is the path to ensure patients get the targeted health care they need to fight disease, and we look forward to partnering with such a renowned medical school to initially focus on four diseases that impact millions of Americans, including many of our health plan members.”

The investment will leverage the university’s cutting-edge research and biomedical capabilities, including state-of-the-art technologies such as CRISPR, and internationally known scientists in the areas of the microbiome, immunomodulatory therapies, cancer genomics, neurodegeneration, cellular reprogramming, chemical biology, informatics and others. In addition, the funds will strengthen resources at more than a dozen centers and institutes at the School of Medicine, including the Edison Family Center for Genome Sciences & Systems Biology; the Andrew M. and Jane M. Bursky Center for Human Immunology and Immunotherapy ProgramsSiteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; the Elizabeth H. and James S. McDonnell III Genome Institute; the Institute for Informatics; and the Center of Regenerative Medicine.

“We will be bringing together world-class resources and intellectual horsepower from every basic and clinical scientific discipline to urgently accelerate the timeline for developing therapies that are more precisely targeted, with aspirations to do so in the next five to seven years,” said David H. Perlmutter, MD, executive vice chancellor for medical affairs, the George and Carol Bauer Dean, and the Spencer T. and Ann. W. Olin Distinguished Professor at the School of Medicine. “I believe the most important advances that will evolve from the personalized medicine paradigm will come from harnessing genome engineering technologies to build better model systems of each human disease, and utilizing deep genomic and clinical characterization to enable more effective and less expensive clinical trials.”

Perlmutter continued, “The partnership supports our global leadership in understanding sequence variants in biological systems that will pave the way for new therapeutic targets, as well as learning more about our own innate biology. Once personalized medicine becomes common practice, health-care workers may examine each patient’s genome — as well as information regarding his or her environment, lifestyle and social network — to identify a customized, affordable approach to optimizing health and medical care.”

Centene and Washington University will host a press briefing at a later date to be determined.

About Centene Corporation
Centene Corporation, a Fortune 100 company, is a diversified, multi-national healthcare enterprise that provides a portfolio of services to government sponsored and commercial healthcare programs, focusing on under-insured and uninsured individuals. Many receive benefits provided under Medicaid, including the State Children’s Health Insurance Program (CHIP), as well as Aged, Blind or Disabled (ABD), Foster Care and Long-Term Services and Supports (LTSS), in addition to other state-sponsored programs, Medicare (including the Medicare prescription drug benefit commonly known as “Part D”), dual eligible programs and programs with the U.S. Department of Defense. Centene also provides healthcare services to groups and individuals delivered through commercial health plans. Centene operates local health plans and offers a range of health insurance solutions. It also contracts with other healthcare and commercial organizations to provide specialty services including behavioral health management, care management software, correctional healthcare services, dental benefits management, commercial programs, home-based primary care services, life and health management, vision benefits management, pharmacy benefits management, specialty pharmacy and telehealth services.

Centene uses its investor relations website to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Centene is routinely posted and is accessible on Centene’s investor relations website, http://www.centene.com/investors.

About Washington University School of Medicine in St. Louis
Washington University School of Medicine’s 1,500 faculty physicians also are the medical staff of Barnes-Jewish and St. Louis Children’s hospitals. The School of Medicine is a leader in medical research, teaching and patient care, ranking among the top 10 medical schools in the nation by U.S. News & World Report. Through its affiliations with Barnes-Jewish and St. Louis Children’s hospitals, the School of Medicine is linked to BJC HealthCare.

Cautionary Statement on Forward-Looking Statements

All statements, other than statements of current or historical fact, contained in this communication are forward-looking statements. Without limiting the foregoing, forward-looking statements often use words such as “believe,” “anticipate,” “plan,” “expect,” “estimate,” “intend,” “seek,” “target,” “goal,” “may,” “will,” “would,” “could,” “should,” “can,” “continue” and other similar words or expressions (and the negative thereof). We intend such forward-looking statements to be covered by the safe-harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and Centene Corporation is including this statement for purposes of complying with these safe-harbor provisions. In particular, these statements include, without limitation, statements about Centene’s future operating or financial performance, market opportunity, growth strategy, competition, expected activities in completed and future acquisitions, including statements about the impact of Centene’s proposed acquisition of WellCare Health Plans, Inc. (the “WellCare Transaction”), Centene’s recent acquisition (the “Fidelis Care Transaction”) of substantially all the assets of New York State Catholic Health Plan, Inc., d/b/a Fidelis Care New York (“Fidelis Care“), investments and the adequacy of Centene’s available cash resources.

These forward-looking statements reflect Centene’s current views with respect to future events and are based on numerous assumptions and assessments made by us in light of Centene’s experience and perception of historical trends, current conditions, business strategies, operating environments, future developments and other factors Centene believes appropriate. By their nature, forward-looking statements involve known and unknown risks and uncertainties and are subject to change because they relate to events and depend on circumstances that will occur in the future, including economic, regulatory, competitive and other factors that may cause Centene’s or its industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. These statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions.

All forward-looking statements included in this filing are based on information available to us on the date of this communication. Except as may be otherwise required by law, Centene undertakes no obligation to update or revise the forward-looking statements included in this communication, whether as a result of new information, future events or otherwise, after the date of this filing. You should not place undue reliance on any forward-looking statements, as actual results may differ materially from projections, estimates, or other forward-looking statements due to a variety of important factors, variables and events including, but not limited to, the following: (i) the risk that regulatory or other approvals required for the WellCare Transaction may be delayed or not obtained or are obtained subject to conditions that are not anticipated that could require the exertion of management’s time and Centene’s resources or otherwise have an adverse effect on Centene; (ii) the risk that Centene’s stockholders do not approve the issuance of shares of Centene common stock in the WellCare Transaction; (iii) the risk that WellCare’s stockholders do not adopt the merger agreement; (iv) the possibility that certain conditions to the consummation of the WellCare Transaction will not be satisfied or completed on a timely basis and accordingly the WellCare Transaction may not be consummated on a timely basis or at all; (v) uncertainty as to the expected financial performance of the combined company following completion of the WellCare Transaction; (vi) the possibility that the expected synergies and value creation from the WellCare Transaction will not be realized, or will not be realized within the expected time period; (vii) the exertion of management’s time and Centene’s resources, and other expenses incurred and business changes required, in connection with complying with the undertakings in connection with any regulatory, governmental or third party consents or approvals for the WellCare Transaction; (viii) the risk that unexpected costs will be incurred in connection with the completion and/or integration of the WellCare Transaction or that the integration of WellCare will be more difficult or time consuming than expected; (ix) the risk that potential litigation in connection with the WellCare Transaction may affect the timing or occurrence of the WellCare Transaction or result in significant costs of defense, indemnification and liability; (x) a downgrade of the credit rating of Centene’s indebtedness, which could give rise to an obligation to redeem existing indebtedness; (xi) unexpected costs, charges or expenses resulting from the WellCare Transaction; (xii) the possibility that competing offers will be made to acquire WellCare; (xiii) the inability to retain key personnel; (xiv) disruption from the announcement, pendency and/or completion of the WellCare Transaction, including potential adverse reactions or changes to business relationships with customers, employees, suppliers or regulators, making it more difficult to maintain business and operational relationships; and (xv) the risk that, following the WellCare Transaction, the combined company may not be able to effectively manage its expanded operations.

Additional factors that may cause actual results to differ materially from projections, estimates, or other forward-looking statements include, but are not limited to, the following: (i) Centene’s ability to accurately predict and effectively manage health benefits and other operating expenses and reserves; (ii) competition; (iii) membership and revenue declines or unexpected trends; (iv) changes in healthcare practices, new technologies, and advances in medicine; (v) increased healthcare costs, (vi) changes in economic, political or market conditions; (vii) changes in federal or state laws or regulations, including changes with respect to income tax reform or government healthcare programs as well as changes with respect to the Patient Protection and Affordable Care Act and the Health Care and Education Affordability Reconciliation Act, collectively referred to as the Affordable Care Act (“ACA”), and any regulations enacted thereunder that may result from changing political conditions or judicial actions, including the ultimate outcome of the District Court decision in “Texas v. United States of America” regarding the constitutionality of the ACA; (viii) rate cuts or other payment reductions or delays by governmental payors and other risks and uncertainties affecting Centene’s government businesses; (ix) Centene’s ability to adequately price products on federally facilitated and state-based Health Insurance Marketplaces; (x) tax matters; (xi) disasters or major epidemics; (xii) the outcome of legal and regulatory proceedings; (xiii) changes in expected contract start dates; (xiv) provider, state, federal and other contract changes and timing of regulatory approval of contracts; (xv) the expiration, suspension, or termination of Centene’s contracts with federal or state governments (including but not limited to Medicaid, Medicare, TRICARE or other customers); (xvi) the difficulty of predicting the timing or outcome of pending or future litigation or government investigations; (xvii) challenges to Centene’s contract awards; (xviii) cyber-attacks or other privacy or data security incidents; (xix) the possibility that the expected synergies and value creation from acquired businesses, including, without limitation, the Fidelis Care Transaction, will not be realized, or will not be realized within the expected time period; (xx) the exertion of management’s time and Centene’s resources, and other expenses incurred and business changes required in connection with complying with the undertakings in connection with any regulatory, governmental or third party consents or approvals for acquisitions, including the Fidelis Care Transaction; (xxi) disruption caused by significant completed and pending acquisitions, including, among others, the Fidelis Care Transaction, making it more difficult to maintain business and operational relationships; (xxii) the risk that unexpected costs will be incurred in connection with the completion and/or integration of acquisition transactions, including, among others, the Fidelis Care Transaction; (xxiii) changes in expected closing dates, estimated purchase price and accretion for acquisitions; (xxiv) the risk that acquired businesses, including Fidelis Care, will not be integrated successfully; (xxv) the risk that, following the Fidelis Care Transaction, Centene may not be able to effectively manage its expanded operations; (xxvi) restrictions and limitations in connection with Centene’s indebtedness; (xxvii) Centene’s ability to maintain the Centers for Medicare and Medicaid Services (CMS) Star ratings and maintain or achieve improvement in other quality scores in each case that can impact revenue and future growth; (xxviii) availability of debt and equity financing, on terms that are favorable to us; (xxxix) inflation; and (xxx) foreign currency fluctuations.

This list of important factors is not intended to be exhaustive. We discuss certain of these matters more fully, as well as certain other factors that may affect Centene’s business operations, financial condition and results of operations, in Centene’s filings with the Securities and Exchange Commission (the “SEC”), including Centene’s Annual Report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K.  Due to these important factors and risks, Centene cannot give assurances with respect to Centene’s future performance, including without limitation Centene’s ability to maintain adequate premium levels or Centene’s ability to control its future medical and selling, general and administrative costs.

 

SOURCE: Centene Corporation

Continue Reading

Agreements

New Partnership to bring UV-LED water purification to the Philippines

Betty Tűndik

Published

on

Reading Time: 2 minutes

 

Acuva Technologies today announced that it has partnered with Kooler Industries, the Philippines’ largest manufacturer of drinking fountains and water dispensers, to bring Acuva UV-LED water purification technology to the Philippine market.

Acuva Technologies, based in British Columbia, Canada, is the world leader in the design, manufacture and integration of advanced UV-LED water purification technology solutions. Acuva’s proprietary technology, developed in partnership with the University of British Columbia, purifies drinking water with disinfection rates of 99% or higher to ensure health and safety. Acuva’s Strike platform of customizable modules is optimized for integration into original equipment manufacturer (OEM) devices, such as those in Kooler Industries’ product lines.

Manoj Singh, President and CEO of Acuva Technologies, stated: “At Acuva, we believe everyone should have access to safe drinking water, which is why we are proud of our partnership with Kooler Industries to bring UV-LED water purification to the Philippines. This first step saves 6 billion single-use water bottles from garbage dumps and landfills, making a significant difference in the war against plastic waste in the Philippines.”

Kooler Industries values innovation and environmental sustainability, which is further affirmed through the partnership with Acuva Technologies,” stated Patrick Cua, General Manager of Kooler Industries. “We look forward to working together to bring revolutionary water disinfection to the Philippine people through the adoption and integration of Acuva’s UV-LED technology in Kooler’s product lines.”

“Canada and the Philippines are partners on the international stage, often working together to find solutions to global issues,” stated John Holmes, Ambassador of Canada to the Philippines. “The collaboration between Acuva Technologies and Kooler Industries is yet another example of the immense opportunity that arises when Canadian and Philippine companies work together to foster innovation and growth.”

About Acuva Technologies
Acuva, a world leader in UVC-LED water disinfection technology, developed its UV-LED water purification systems to enable clean drinking water globally. Acuva’s Strike platform of customizable UV-LED modules is designed for ease of OEM integration into consumer and commercial water dispensing appliances. Advanced applications also include integration into lab water equipment. Acuva’s technology provides a sustainable solution for OEMs phasing out conventional UV lamp systems to comply with the Minamata Convention, a United Nations Environmental Program with a mandate to encourage phasing out mercury by 2020.

About Kooler Industries
Kooler Industries is the Philippines’ largest manufacturer and distributor of drinking fountains, and has been setting the standard since 1972. A trusted supplier and service provider for heating, refrigeration, and hygienic products, Kooler is committed to product standards, customer satisfaction, and protecting the environment. Kooler Industries is No. 1 in leasing drinking fountains in the Philippines, with units located in factories, schools, shopping malls, restaurants, fast food outlets, resorts and country clubs. All water dispensers are proudly Philippine-made and are engineered for local conditions.

 

SOURCE: Acuva Technologies

Continue Reading

Font Resizer

Subscribe to PICANTE via Email

Enter your email address to subscribe to PICANTE and receive notifications of new posts by email.

Follow us on Facebook

Read more from our authors

Follow our Tweets

Trending

Please turn AdBlock off